PMID- 38434917
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240305
IS  - 2732-7787 (Electronic)
IS  - 2732-7787 (Linking)
VI  - 4
IP  - 2
DP  - 2024 Mar-Apr
TI  - Evaluation of Atezolizumab Plus Bevacizumab Versus Modified Lenvatinib Therapy in 
      Child-Pugh A Unresectable Hepatocellular Carcinoma.
PG  - 122-128
LID - 10.21873/cdp.10297 [doi]
AB  - BACKGROUND/AIM: Atezolizumab/bevacizumab (Atez/BV) and lenvatinib (LEN) are the 
      recommended first-line treatments for patients with unresectable hepatocellular 
      carcinoma (HCC). Previous reports have suggested that the tolerability and 
      therapeutic efficacy of LEN could be enhanced by modifying its administration 
      method. Therefore, this study compared the efficacy and safety of Atez/BV, the 
      standard LEN therapy (standard LEN), and modified LEN therapy (modified LEN). 
      PATIENTS AND METHODS: The overall survival (OS) and the rate of discontinuation 
      due to adverse events (AEs) were compared between groups treated with Atez/BV 
      (n=36), standard LEN (n=30), and modified LEN (n=11). RESULTS: Discontinuation 
      due to AEs was required in 22.2%, 23.3%, and 9.1% of patients in the Atez/BV, 
      standard LEN, and modified LEN groups (p=0.485). The median OS for the Atez/BV, 
      standard LEN, and modified LEN groups was 523 [95% confidence interval 
      (CI)=163-818], 382 (95%CI=330-547), and 604 (95% CI=257-656) days, respectively 
      (log-rank test, p=0.949). CONCLUSION: Atez/BV and the standard and modified LEN 
      regimens showed comparable efficacy and safety.
CI  - Copyright 2024, International Institute of Anticancer Research.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
FAU - Yamada, Shiori
AU  - Yamada S
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
FAU - Go, Makiko
AU  - Go M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
FAU - Yasuda, Satoshi
AU  - Yasuda S
AD  - Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, 
      Japan.
FAU - Toyoda, Hidenori
AU  - Toyoda H
AD  - Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, 
      Japan.
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
LA  - eng
PT  - Journal Article
DEP - 20240303
PL  - Greece
TA  - Cancer Diagn Progn
JT  - Cancer diagnosis & prognosis
JID - 9918316186306676
PMC - PMC10905284
OTO - NOTNLM
OT  - Atezolizumab
OT  - bevacizumab
OT  - first-line treatment
OT  - lenvatinib
OT  - overall survival
OT  - unresectable hepatocellular carcinoma
COIS- The Authors declare no conflicts of interest in relation to this study.
EDAT- 2024/03/04 06:42
MHDA- 2024/03/04 06:43
PMCR- 2024/03/03
CRDT- 2024/03/04 04:52
PHST- 2024/01/05 00:00 [received]
PHST- 2024/01/26 00:00 [accepted]
PHST- 2024/03/04 06:43 [medline]
PHST- 2024/03/04 06:42 [pubmed]
PHST- 2024/03/04 04:52 [entrez]
PHST- 2024/03/03 00:00 [pmc-release]
AID - 10.21873/cdp.10297 [doi]
PST - epublish
SO  - Cancer Diagn Progn. 2024 Mar 3;4(2):122-128. doi: 10.21873/cdp.10297. eCollection 
      2024 Mar-Apr.